PT86640A - Hepatitis b virus surface antigens and hybrid antigens containing them - Google Patents

Hepatitis b virus surface antigens and hybrid antigens containing them

Info

Publication number
PT86640A
PT86640A PT86640A PT8664088A PT86640A PT 86640 A PT86640 A PT 86640A PT 86640 A PT86640 A PT 86640A PT 8664088 A PT8664088 A PT 8664088A PT 86640 A PT86640 A PT 86640A
Authority
PT
Portugal
Prior art keywords
antigens
hepatitis
hybrid
virus surface
surface antigens
Prior art date
Application number
PT86640A
Other languages
English (en)
Other versions
PT86640B (pt
Inventor
Teresa Cabezon
Michel De Wilde
Nigel Harford
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of PT86640A publication Critical patent/PT86640A/pt
Publication of PT86640B publication Critical patent/PT86640B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT86640A 1987-01-30 1988-01-27 Processo de preparacao de antigenios de superficie do virus b de hepatite e de antigenios/hibridos que os contem PT86640B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (2)

Publication Number Publication Date
PT86640A true PT86640A (pt) 1988-02-01
PT86640B PT86640B (pt) 1992-01-31

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
PT86640A PT86640B (pt) 1987-01-30 1988-01-27 Processo de preparacao de antigenios de superficie do virus b de hepatite e de antigenios/hibridos que os contem

Country Status (20)

Country Link
EP (1) EP0278940A3 (pt)
JP (1) JPS6463382A (pt)
KR (1) KR880009130A (pt)
CN (1) CN1031395A (pt)
AP (1) AP56A (pt)
AU (1) AU1093088A (pt)
DD (3) DD285994A5 (pt)
DK (1) DK43188A (pt)
FI (1) FI880428A (pt)
HU (1) HUT50876A (pt)
IL (1) IL85216A0 (pt)
MA (1) MA21169A1 (pt)
NO (1) NO880395L (pt)
NZ (1) NZ223297A (pt)
OA (1) OA08801A (pt)
PT (1) PT86640B (pt)
SU (1) SU1746887A3 (pt)
TN (1) TNSN88004A1 (pt)
YU (1) YU17488A (pt)
ZA (1) ZA88488B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10299017I2 (de) 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid.
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
EP0345792A3 (en) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
DK0614465T3 (da) * 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
ATE199158T1 (de) * 1991-12-23 2001-02-15 Bayer Ag Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
BR9305435A (pt) * 1992-03-06 1994-12-27 Innogenetics Nv Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
EP0835663B1 (en) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
EP2397856B1 (en) 2006-03-14 2013-11-13 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
US8188214B2 (en) 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2142211A1 (en) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccine
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
EP0171908A3 (en) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
EP0225887B1 (en) * 1985-04-08 1994-06-08 Amgen Inc. A method and a hybrid promoter for controlling exogenous gene transcription
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein

Also Published As

Publication number Publication date
DD284899A5 (de) 1990-11-28
DK43188A (da) 1988-07-31
MA21169A1 (fr) 1988-10-01
TNSN88004A1 (fr) 1990-07-10
PT86640B (pt) 1992-01-31
NO880395L (no) 1988-08-01
YU17488A (en) 1991-02-28
AP8800078A0 (en) 1987-11-01
FI880428A (fi) 1988-09-13
OA08801A (fr) 1989-03-31
AU1093088A (en) 1988-08-04
DD285612A5 (de) 1990-12-19
EP0278940A2 (en) 1988-08-17
IL85216A0 (en) 1988-07-31
JPS6463382A (en) 1989-03-09
SU1746887A3 (ru) 1992-07-07
CN1031395A (zh) 1989-03-01
KR880009130A (ko) 1988-09-14
FI880428A0 (fi) 1988-01-29
NZ223297A (en) 1991-06-25
AP56A (en) 1989-09-26
DK43188D0 (da) 1988-01-28
NO880395D0 (no) 1988-01-29
HUT50876A (en) 1990-03-28
EP0278940A3 (en) 1988-12-07
DD285994A5 (de) 1991-01-10
ZA88488B (en) 1988-10-26

Similar Documents

Publication Publication Date Title
PT86640A (pt) Hepatitis b virus surface antigens and hybrid antigens containing them
FI945483A (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
HK38293A (en) Hepatitis c virus
GB2212511B (en) Hepatitis c virus
DK603888A (da) Rekombinant virus
DK213987A (da) Hepatitis b-peptidimmunogen
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
KR890701743A (ko) B형 간염 표면 항원 백신
GB8816233D0 (en) Rubella e1 glycoprotein antigens
IL79740A0 (en) Hepatitis vaccine
GB8621578D0 (en) Hepatitis b viral antigens
ZA874498B (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
GB8622883D0 (en) Expression of hepatitis b viral antigens
IE851705L (en) Hepatitis B Virus Surfact Antigen and Production Thereof
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
NZ215820A (en) Hepatitis b antigen formed by recombinant dna techniques
IE880242L (en) Hepatitis b virus antigens.
JPS54101421A (en) Hepatitis b surface antigen
IE852110L (en) Recombinant hepatitis antigen
IE861419L (en) Isolation of hepatitis b surface antigen
GB8703864D0 (en) Bluetongue virus antigens
GB8709779D0 (en) Bluetongue virus antigens
FI95726C (fi) Diagnostiset menetelmät ja määrityssarjat, joissa käytetään yhdistelmä-DNA-tekniikalla muodostettua hepatitis B -viruksen pinta-antigeenia
GB8708532D0 (en) Particulate hybrid hiv antigens
IE820073L (en) Preparing hepatitis b surface antigen

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940131